A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
Alessio Cortellini, A.P.C. Barrichello, Joao V. Alessi, B. Ricciuti, Victor R. Vaz, Thomas Newsom-Davis, J.S. Evans, Giuseppe Lamberti, Federica Pecci, Peter Viola, A. D’Alessio, Claudia Angela Maria Fulgenzi, Mark M. Awad, David J. Pinato
Topics & Concepts
MedicinePembrolizumabInternal medicineLung cancerOncologyNivolumabIpilimumabImmunotherapyEveningCancerMorningAstronomyPhysicsCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCircadian rhythm and melatonin